| SRPT Stock | | | USD 137.94 7.44 5.70% |
CFO
Ian Estepan is Executive CFO of Sarepta Therapeutics
| Age | 48 |
| Address | 215 First Street, Cambridge, MA, United States, 02142 |
| Phone | 617 274 4000 |
| Web | https://www.sarepta.com |
Sarepta Therapeutics Management Efficiency
The company has return on total asset
(ROA) of
0.0151 % which means that it generated a profit of $0.0151 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity
(ROE) of
0.1227 %, meaning that it created $0.1227 on every $100 dollars invested by stockholders. Sarepta Therapeutics' management efficiency ratios could be used to measure how well Sarepta Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.
Return On Tangible Assets is likely to drop to -0.17 in 2024.
Return On Capital Employed is likely to drop to -0.11 in 2024. At this time, Sarepta Therapeutics'
Total Current Liabilities is comparatively stable compared to the past year.
Liabilities And Stockholders Equity is likely to gain to about 3.4
B in 2024, whereas
Non Current Liabilities Other is likely to drop slightly above 39
M in 2024.
Sarepta Therapeutics currently holds 1.4
B in liabilities with Debt to Equity
(D/E) ratio of 3.72, implying the company greatly
relies on financing operations through barrowing. Sarepta Therapeutics has a current ratio of 4.27, suggesting that it is
liquid enough and is able to pay its financial obligations when due. Note, when we think about Sarepta Therapeutics' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Found 1 records | CFO Age |
| Mardi Dier | Madrigal Pharmaceuticals | 60 |
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. Sarepta Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 840 people. Sarepta Therapeutics (SRPT) is traded on NASDAQ Exchange in USA. It is located in 215 First Street, Cambridge, MA, United States, 02142 and employs 1,314 people. Sarepta Therapeutics is listed under Biotechnology category by Fama And French industry classification.
Management Performance
Sarepta Therapeutics Leadership Team
Elected by the shareholders, the Sarepta Therapeutics' board of directors comprises two types of representatives: Sarepta Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sarepta. The board's role is to monitor Sarepta Therapeutics' management team and ensure that shareholders' interests are well served. Sarepta Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sarepta Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| William Ciambrone, Ex Operations | |
| Dallan Murray, Executive Officer | |
| Ian Estepan, Executive CFO | |
| Ryan JD, General VP | |
| Will Tilton, Head VP | |
| Douglas Esq, CEO President | |
| Louise RodinoKlapac, Chief VP | |
| Alison Nasisi, Executive Officer | |
| Bilal Arif, Executive Officer | |
| Diane Berry, Executive Officer | |
| Ryan Brown, Gen VP | |
| Mary Jenkins, Senior Relations | |
| Francesca Nolan, Executive Communications | |
Sarepta Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sarepta Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Additional Tools for Sarepta Stock Analysis
When running Sarepta Therapeutics' price analysis, check to
measure Sarepta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sarepta Therapeutics is operating at the current time. Most of Sarepta Therapeutics' value examination focuses on studying past and present price action to
predict the probability of Sarepta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sarepta Therapeutics' price. Additionally, you may evaluate how the addition of Sarepta Therapeutics to your portfolios can decrease your overall portfolio volatility.